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divided by the total number of days). RESULTS: Most of the
62,754 beneﬁciaries had an index prescription of BETA, fol-
lowed by ACEi, DIU, CCB, and ARB. Persistence rates at 180
and 360 days were highest for ARB (71.0 and 52.7%, valsartan
77.1 and 59.3%), followed by CCB (51.5 and 34.4%), ACEi
(50.2 and 34.5%), DIU (41.3 and 26.0%), and BETA (25.1 and
13.6%). After adjusting for age, sex, and diabetic comorbidity,
the persistence remained signiﬁcantly higher for ARB compared
to all other drug classes. The MPR for 180 and 360 days showed
a similar pattern with the highest ratio for ARB (0.88 and 0.84;
valsartan 0.92 and 0.87), followed by CCB (0.73 and 0.66),
ACEi (0.72 and 0.67), DIU (0.70 and 0.63), and BETA (0.51 and
0.45). CONCLUSION: ARBs, and valsartan as a representative
of the class, showed the highest persistence and compliance sug-
gesting that a more sustained blood pressure control could be
expected from utilization of ARBs and Valsartan.
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Lack of compliance is a major factor responsible for the differ-
ences between clinical trial results and real effectiveness in daily
medical practice, contributing to an insufﬁcient control of the
cardiovascular risk factors (CVRF). Knowledge of the factors
contributing to lack of compliance is limited, and in Spain data
are scarce. OBJECTIVES: 1) To indirectly determine the level of
compliance among patients with hypertension and/or dyslipi-
demia; 2) To determine factors associated with compliance.
Patients and METHODS: A total of 9001 hypertensive and/or
dyslipidemic patients from four primary care centres in Catalo-
nia were enrolled in Disease Management programmes during
the previous four years. Compliance was estimated by the rela-
tionship between the amount of dispensed and prescribed pills.
1) The levels of compliance of dyslipidemic patients without
hypertension (DL-non HT), hypertensive patients with dyslipi-
demia (HT + DL) and hypertensives without dyslipidemia 
(HT-non DL) were compared. 2) An stepwise, multivariate,
descriptive; multiple regression model was designed in order to
explain compliance. RESULTS: 1) Compliance was 79% in DL-
non HT, signiﬁcantly lower than in HT + DL (81.2%, p <
0.0001) and in HT-non DL (82.4%, p < 0.0001). There were
also statistically signiﬁcant differences between these last two
groups (p = 0.0014). 2) Explanatory variables of a better com-
pliance in the multivariate analysis were a) patient related
factors: labour inactivity (p < 0.0001); b) management related
factors: speciﬁc doctor (p < 0.0001) and intensity of follow-up
(p = 0.04) and c) drug related factors: the drug group (p <
0.0001); the drug price (the more price the more compliance (p
= 0.0062) and the number of active principles used (the more
number the more compliance, p = 0.019). CONCLUSIONS: 1)
Dyslipidemic patients show a worse compliance than hyperten-
sive patients, and dyslipidemia worsened global compliance in
hypertensive patients. 2) Patient characteristics, doctor attitude,
follow-up intensity, drug group and simplicity of treatment are
related to compliance in daily medical practice.
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OBJECTIVES: To evaluate the long-term clinical and cost out-
comes of adding Niaspan® to statin treatment in patients with
persistently low HDL-c on statin monotherapy. METHODS:
Two models were developed to project long-term clinical and
economic outcomes. The ﬁrst model (second order Monte Carlo
simulation) simulated the evolution of lipid levels with treatment
and the second (Markov model) was designed to calculate the
risk of coronary heart disease (CHD) events each subsequent
year. Transition probabilities for CHD events were derived from
the Framingham risk formulae. Baseline cohort characteristics
and simvastatin treatment effects were taken from the 4S lipid
triad sub-group. Patients with persistently low HDL-c 
(<1.03mmol/L) on statin treatment received either add-on
Niaspan® 1g to 2g daily or continued statin monotherapy.
Niaspan® dosing followed maintenance dose recommendations
and treatment effects were taken from several clinical trials
(European SPC). Direct medical costs were accounted (cardio-
vascular complications and drug costs). Annual discount rates of
0% and 3.5% (Austria), 3% (Sweden and Norway) were applied
to clinical outcomes and costs. RESULTS: 68.9% of patients
were projected to have persistently low HDL-c levels after statin
treatment. In these patients mean undiscounted life expectancies
(LE) of 20.96 years and 20.46 years were projected for the
Niaspan® and statin monotherapy arms respectively. Lifetime
direct medical costs were higher by €8079 in Austria, €4723 in
Sweden and €5638 in Norway with addition of Niaspan®. Incre-
mental cost-effectiveness ratios based on discounted LE were
€16,306 (€17,635) per life year gained in Austria, €16,543
(€16,652) in Sweden and €19,748 (€21,194) in Norway for
statin plus Niaspan® 1g (and 2g) versus statin monotherapy.
CONCLUSIONS: In Austria, Sweden and Norway, raising HDL-
c with the addition of Niaspan® to statin therapy was projected
to be cost-effective compared to statin monotherapy in patients
with dyslipidemia and persistently low HDL-c.
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OBJECTIVES: To evaluate the long-term clinical and cost out-
comes of adding Niaspan® to statin treatment in patients with
persistently low HDL-c on statin monotherapy. METHODS:
Two models were developed to project long-term clinical and
economic beneﬁts of treatment. The ﬁrst simulated the evolution
of lipid levels with treatment utilising second order Monte Carlo
methodology, and the second was designed to calculate the risk
of coronary heart disease (CHD) events each subsequent year
using standard Markov modeling techniques. Transition proba-
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bilities for CHD events were derived from the Framingham risk
formulae. Baseline cohort characteristics and Niaspan® treat-
ment effects were taken from the ARBITER II study. Patients
with persistently low HDL-c (<1.03 mmol/L) on statin treatment
received either add-on Niaspan® 1g daily or continued statin
monotherapy. Direct costs (2004 Euros) were accounted (car-
diovascular disease and treatment costs). Annual discount rates
of 5% (Germany) and 3.5% (UK) were applied to clinical out-
comes and costs. Undiscounted life expectancy (LE) was also cal-
culated. Sensitivity analyses were performed. RESULTS: A total
of 53.75% of patients were projected to have persistently low
HDL-c levels after statin treatment. In these patients mean undis-
counted LE of 16.12 years and 15.85 years were projected for
the Niaspan® and statin monotherapy arms respectively. Lifetime
direct medical costs were higher by €3563 in Germany and by
£2820 in the UK with addition of Niaspan®. Incremental cost-
effectiveness ratios based on discounted LE were €26,624 per life
year gained in Germany and £17,262 in the UK for statin plus
Niaspan® versus statin monotherapy. Results were most sensitive
to the gender distribution, as women have a lower risk of CHD
events. CONCLUSIONS: In patients with dyslipidemia and per-
sistently low HDL-c, addition of Niaspan® to statin therapy was
projected to be cost-effective compared to statin monotherapy in
Germany and the UK.
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OBJECTIVES: To estimate the medical costs directly related to
the Metabolic Syndrome (MS) in Italy. METHODS: A retro-
spective study was conducted on a general sample of 4.974
patients, to whom an oral blood glucose lowering drug, a serum
lipid reducing agent and an antihypertensive drug had been pre-
scribed at least once during the observation period (2001–2003).
An equal sized control group (matched by sex and age) and a
sub-sample of 1.401 patients from the general sample (actual
consumers of the above prescribed drugs at least once in each of
the observational years) were also used. The general and sub-
sample showed no considerable differences in the primary out-
comes. All data was obtained from a Northern Local Health Unit
database. The prospective was the Italian NHS’s point of view.
The speciﬁc costs of the MS (drugs and hospitalisation) were cal-
culated as incremental costs, comparing the affected patients
(study group) to the general population (control group).
RESULTS: The Metabolic Syndrome affects both males (49.5%,
mean age 64.6) and females (50.5%, mean age 68.2). Yearly
mortality among patients with MS does not differ from mortal-
ity in the general population. All the costs in the study group
were signiﬁcantly higher than the corresponding costs in the
control group. The total average cost per year for a patient with
MS was estimated at €1522 (drugs: €558; hospitalisation: €964),
versus the lower corresponding estimation for the general 
population at €361 (drugs: €155; hospitalisation: €206). So, on
a yearly and per capita basis, the incremental cost of the meta-
bolic syndrome amounts to €1161.Mortality and age were
shown to be the major cost drivers. CONCLUSIONS: To the
NHS in Italy the cost for MS might be as high as €670 million
a year (0.9% of the total public health expenditure).
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OBJECTIVES: To assess the long-term cost-effectiveness of titra-
tion from initial doses of rosuvastatin (RSV) and generic sim-
vastatin (SIM). METHODS: Efﬁcacy data from the STELLAR
clinical trial (TC, HDL-C, and TG) were used as input to the
model. Markov models ran in 4-year cycles for 20 years, from
age 55 to 76 years to predict primary and secondary CHD based
on Framingham risk equations in four gender/risk cohorts. In
year one quarterly titration up to a maximum dose of 40mg
(RSV) or 80mg (SIM) was based on a total cholesterol (TC)
target of 5mmol/l. Risk was calculated using the average TC:
HDL-C ratio of 1000 simulated patients, with adjustment for
Framingham’s hypothesised over-prediction of UK risk. RSV and
generic SIM prices for September 2004 and recent UK CHD
event cost data were applied. Relative mortality risks and health-
state utilities were used to derive quality-adjusted life years
(QALYs). Discounting was performed at 3.5% (costs and out-
comes). RESULTS: The STELLAR trial found RSV 10mg
lowered total cholesterol signiﬁcantly more than SIM 10–40mg
(-32.9% vs. -20.3%, -25.7%, 27.9%, respectively), and RSV
20mg lowered total cholesterol signiﬁcantly more than SIM 
80mg (-37.6% vs. -32.9%). Based on this model less CHD
events and deaths are expected among patients on RSV com-
pared with SIM. Hence RSV delivers more QALYS at an accept-
able cost per patient, e.g. £3458 per QALY for high-risk males
compared with SIM. Insensitivity analysis when generic SIM is
priced at zero, the cost per QALY gained for RSV ranged from
£11,169 (male high risk) to £21,752 (female base case). CON-
CLUSIONS: More CHD events are likely to be avoided using
RSV than SIM. RSV will be a cost-effective strategy, as deﬁned
by UK NICE thresholds for cost per QALY gained, even as the
generic SIM price approaches zero.
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OBJECTIVES: To understand the patterns of aspirin utilization
among users of Nonsteroidal Anti-Inﬂammatory Drugs
(NSAIDs) with varying cardiovascular risk proﬁles. METHODS:
A telephone survey was completed using a large health beneﬁts
company population. The survey consisted of 10-items used to
characterize aspirin consumption and identify motivation for 
utilization. Subjects were randomly selected from a dataset of
members aged 18 and older, who had an NSAID prescription
claim between April 1, 2003 and June 30, 2003, while main-
taining continuous plan enrollment during a 24-month period.
Subjects were also required to maintain chronic NSAID utiliza-
tion, deﬁned as at least a 90 days’ supply during a 12-month
period. Study subjects were stratiﬁed based upon their NSAID
utilization into: 1) cox-II selective inhibitors; 2) non-selective
NSAIDs (excluding naproxen); and 3) naproxen. Subjects were
further stratiﬁed based upon the presence or absence of risk
factors associated with cardiovascular events. RESULTS: The
study population consisted of 1250 subjects, of which 52.3%
were treated with non-selective NSAIDs, 19.4% with naproxen,
and 28.3% with cox-II inhibitors. In total, 77.1% of the popu-
